pa 1

Pediocin PA-1, a broad-spectrum lactic acid bacterial bacteriocin, inhibits the activity of foodborne pathogens including Listeria monocytogenes and Gram-positive bacteria, and can be utilized as a food biopreservative [1].

Pediocin PA 1 TFA is a broad-spectrum bacteriocin produced by lactic acid bacteria, inhibiting the activity of foodborne pathogens such as Listeria monocytogenes and other Gram-positive bacteria. It has applications as a biopreservative in food products.

18:0-18:1 PA (1-Stearoyl-2-oleoyl-sn-glycero-3-phosphate) sodium is an anionic lipid.

1-Palmitoyl-2-oleoyl-sn-glycero-3-PA (1,2-POPA) is a phospholipid featuring a palmitic acid (16:0) chain that is saturated and an oleic acid (18:1) chain that is monounsaturated, positioned at the sn-1 and sn-2 locations, respectively. This compound is utilized in creating micelles, liposomes, and various artificial membrane forms.

1-Palmitoyl-d9-2-hydroxy-sn-glycero-3-PA (1-palmitoyl-d9LPA) serves as an internal standard for the quantification of 1-palmitoyl LPA using GC- or LC-MS. This compound, an analog of LPA with palmitic acid at the sn-1 position, activates reporter gene expression in PC12 cells fitted with human lysophosphatidic acid receptor 4 (LPA4) at 0.01 to 10 µM concentrations. Additionally, 1-palmitoyl LPA prompts aggregation in isolated human platelets within the 12-300 µM range, a process reversible by prostaglandin E1 (PGE1), theophylline, or EDTA. It also interacts with calcium and magnesium to boost the efficacy of ampicillin, piperacillin, and ceftazidime against P. aeruginosa strains from cystic fibrosis patients.

(D)-PPA 1 TFA, a hydrolysis-resistant D-peptide antagonist, is a potent PD-1 PD-L1 inhibitor with an affinity for PD-1 of 0.51 μM, demonstrating efficacy both in vitro and in vivo [1].

PD-1/PD-L1 interaction inhibitor. Binds to PD-L1 (Kd = 0.51 μM). Inhibits interaction at 1 mg/mL in flow cytometry. Inhibits tumor growth and prolongs survival time of mice in vivo.

Cyclophosphamide is an alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.

mTOR HDAC-IN-1 (Compound 50) is a dual inhibitor of mTOR and HDAC, with IC50 values of 0.49 nM and 0.91 nM, respectively, holding potential as an anti-cancer agent [1].

Bencycloquidium Bromide is a muscarinic M3 antagonist. Bencycloquidium bromide inhibits nasal hypersecretion in a rat model of allergic rhinitis. Bencycloquidium Bromide showed high affinity toward the M(3) receptor in Chinese hamster ovary (CHO) cells (M(1) pKi=7.86, M(2) pKi=7.21, M(3) pKi=8.21); pA(2)=8.85, 8.71 and 8.57 in methacholine-induced contraction of trachea, ileum and urinary bladder, 8.19 in methacholine-induced bradycardia of right atrium in vitro, respectively.This compound is unstable in powder form and other related salt forms are recommended.

U-73343 is an inactive analog of U-73122 and can be used as a negative control. It dose-dependently inhibits acid secretion irrespective of the stimulant. It is a phospholipase C (PLC) and 5-LO (5-lipoxygenase) inhibitor with an IC50 of 1-2.1 μM for PLC.

PROTAC IRAK4 degrader-1 (compound I-210) is a Cereblon based PROTAC consisting of the PROTAC IRAK4 ligand-1, the E3 ligase ligand Pomalidomide and the PROTAC linker AM-Imidazole-PA-Boc.

IK1 inhibitor PA-6 (PA-6) is a selective and potent inhibitor of IK1 (KIR2.x ion-channel-carried inward rectifier current) with an IC50 of 12-15 nM for human and mouse KIR2.x currents.

(+)-JQ1 PA, a derivative of the Bromodomain and extra-terminal (BET) inhibitor JQ1, exhibits an IC50 of 10.4 nM.

AM-Imidazole-PA-Boc is an alkyl chain-derived PROTAC linker used for the synthesis of PROTAC IRAK4 degrader-1[1].

1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium is a salt form compound.1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate is a lipid and endogenous metabolite related to LPA (lysophosphatidic acid).

AP39 Prodrug 1 (Compound M1) is a mitochondria-targeted H2S prodrug. In hepatocytes, it induces ROS-dependent mild mitochondrial uncoupling, activates mitochondria-associated AMPK, and inhibits Palmitic acid (PA)-induced lipid accumulation.

PA1 2HCl is a blocker of photoswitchable epithelial sodium channel (ENaC). PA1 2HCl enables the optical control of ENaC channels, in particular the δβγ isoform, by switching between blue and green light, or by turning on and off blue light.

Paclitaxel-SMCC is a paclitaxel derivative with a SMCC linker. (Succinimidyl-4-( N -maleimidomethyl)cyclohexane-1-carboxylate). Paclitaxel-SMCC can be used to synthesize Paclitaxel bioconjugates with enzymes, antobodies, antigens and other biopolymers. Pa

Hirudin (54-65; non-sulfated) is a desulfated peptide fragment of hirudin, an anticoagulant produced byH. medicinalis.1It inhibits fibrin clot formation induced by isolated bovine thrombin with an IC50value of 3.7 μM.2 1.Niehrs, C., Huttner, W.B., Carvallo, D., et al.Conversion of recombinant hirudin to the natural form by in vitro tyrosine sulfation. Differential substrate specificities of leech and bovine tyrosylprotein sulfotransferasesJ. Biol. Chem.265(16)9314-9318(1990) 2.Payne, M.H., Krstenansky, J.L., Yates, M.T., et al.Positional effects of sulfation in hirudin and hirudin PA related anticoagulant peptidesJ. Med. Chem.34(3)1184-1187(1991)

MRTX9768 hydrochloride is a potent, orally active PRMT5 inhibitor. MRTX9768 hydrochloride is a synthetic lethal-based inhibitor binding the PRMT5-MTA complex[1]. MRTX9768 inhibits SDMA and cell proliferation in HCT116 MTAP-del cells (SDMA IC50 3 nM; prolif. IC50 11 nM) with marked selectivity over HCT116 MTAP-WT cells (SDMA IC50 544 nM; prolif. IC50 861 nM)[1].MRTX9768 selectively targets MTAP CDKN2A-deleted tumors[2][1]. In xenograft studies, oral administration of MRTX9768 demonstrates dose-dependent inhibition of SDMA in MTAP-del tumors, with less SDMA modulation observed in bone marrow[1]. [1]. Christopher R. Smith, et al. Abstract LB003: Fragment based discovery of MRTX9768, a synthetic lethal-based inhibitor designed to bind the PRMT5-MTA complex and selectively target MTAP CDKN2A-deleted tumors. AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA.[2]. Yingqing Chen, et al. Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms. Biomed Pharmacother. 2021 Oct 4;144:112252.

PA Nic is a coumarin-caged nicotine. Releases nicotine when exposed to 390 ± 10 nm wavelength light (λmax = 404 nm). Suitable for two-photon uncaging at <900 nm (Maximum two-photon cross-section at 810 nm). Extinction coefficient (ε) 17,400 M-1cm-1. Evokes nicotinic currents in mouse brain slices under one and two-photon activation conditions.

Bevirimat (PA-457) is a first-in-class inhibitor of HIV-1 maturation, blocking the cleavage of the Gag capsid (CA) precursor, CA-SPI, to mature CA protein during virion maturation.

ATP Synthase Inhibitor 2, a compound targeting Pseudomonas aeruginosa (PA) ATP synthase with an IC50 of 10 μg mL, fully inhibits the ATP synthesis activity of PA at a concentration of 128 μg mL [1].